Intangible asset measurement input.

No definition available.

Name:	armp_IntangibleAssetMeasurementInput
Namespace Prefix:	armp_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

No definition available.

+ Details

Name:	armp_ProceedsFromEquityOfferingsGross
Namespace Prefix:	armp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

+ Details

Name:	us-gaap_CommonStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228

+ Details

Name:	us-gaap_ImpairmentOfLongLivedAssetsHeldForUse
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_IncomeTaxCreditsAndAdjustments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of other current and other deferred income tax expense (benefit) attributable to continuing operations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)-(b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

+ Details

Name:	us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperations
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

+ Details

Name:	us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of unrecognized tax benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319

+ Details

Name:	us-gaap_UnrecognizedTaxBenefits
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	dei_LegalEntityAxis=armp_AmpliphiBiosciencesCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=armp_StaphProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=armp_PseudomonasProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=armp_C3jTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Accounting Policies (Narrative) (Details)					3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended		24 Months Ended
Significant Accounting Policies (Narrative) (Details)	May 09, 2019	Mar. 22, 2018 USD ($)	Jan. 12, 2018 USD ($)	Apr. 24, 2017 $ / shares shares	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Sep. 30, 2019 $ / shares shares	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Apr. 23, 2017 shares
In-process research and development									$ 5,691,000
Conversion ratio of reverse stock split								0.0714
Common stock, par value (in dollars per share) \| $ / shares								$ 0.01		$ 0.01
Common stock, shares authorized \| shares								217,000,000		217,000,000
AmpliPhi Biosciences Corporation [Member]
Impairment of long-lived assets												$ 0
Proceeds from equity offerings, gross		$ 3,000,000	$ 4,000,000
Reverse stock split, description										1 -for-10 (1:10) reverse stock split of its common stock, par value $0.01 per share
Conversion ratio of reverse stock split				10
Common stock, par value (in dollars per share) \| $ / shares				$ 0.01						$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized \| shares				67,000,000						217,000,000	67,000,000	67,000,000	670,000,000
AmpliPhi Biosciences Corporation [Member] \| Domestic Tax Authority [Member] \| Research Tax Credit Carryforward [Member]
Unrecognized tax benefits										$ 1,700,000	$ 2,100,000	$ 2,100,000
AmpliPhi Biosciences Corporation [Member] \| Australian Taxation Office [Member]
Tax rebates received					$ 1,200,000	$ 2,000,000
AmpliPhi Biosciences Corporation [Member] \| Staph Program [Member]
Impairment of long-lived assets										$ 0
In-process research and development							$ 2,800,000
AmpliPhi Biosciences Corporation [Member] \| Staph Program [Member] \| Measurement Input, Discount Rate [Member]
Intangible asset measurement input										19.4
AmpliPhi Biosciences Corporation [Member] \| Pseudomonas Program [Member]
In-process research and development							1,900,000
AmpliPhi Biosciences Corporation [Member] \| In Process Research and Development [Member]
Impairment of in-process research and development							5,800,000			$ 1,900,000	5,800,000
Income tax expense (benefit) relating to impairment charge							$ (1,300,000)			(328,000)	$ 1,300,000
AmpliPhi Biosciences Corporation [Member] \| Patents [Member]
Finite-lived intangible assets, gross										493,000
Accumulated amortization										248,000
C3J [Member]
Impairment of long-lived assets										0
In-process research and development										$ 5,691,000
Conversion ratio of reverse stock split	0.0714
Common stock, par value (in dollars per share) \| $ / shares										$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized \| shares										217,000,000	217,000,000	217,000,000